Mature T Cell And Nk Cell Non Hodgkin Lymphoma C5551485
A cancer of mature T cells and natural killer cells, a rare type of non-Hodgkin lymphoma. Can affect adults. Treated with chemotherapy and newer targeted therapies; prognosis varies.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized lymphadenopathy
(hematologic)Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Unexplained weight loss
(systemic)Fever
(systemic)Peripheral neuropathy
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Chemotherapy Regimen
Multi-agent chemotherapy is the cornerstone of treatment, typically using regimens like CHOP or more intensive protocols depending on disease subtype and stage. Treatment requires careful monitoring of hematologic parameters and organ function throughout the course.
Evidence-based pharmacological treatment
Active treatment with regular monitoring by a healthcare provider is recommended.
Autologous Stem Cell Transplantation
High-dose chemotherapy followed by stem cell rescue is considered for eligible patients with relapsed or refractory disease. This procedure aims to restore bone marrow function after intensive treatment.
Additional treatment options
Radiation Therapy
Localized radiation may be used for disease consolidation or symptom palliation in specific presentations. It targets affected lymph nodes or extranodal sites with precise dosing protocols.
procedureClinical Trial Participation
Novel agents and immunotherapies are being investigated in clinical trials for T-cell and NK-cell lymphomas. Participation may provide access to targeted treatments not yet widely available.
monitoringSupportive Care and Lifestyle Modification
Comprehensive supportive care including infection prevention, nutritional support, and psychological services improves quality of life during treatment. Regular exercise when tolerated supports overall recovery.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Mature T Cell And Nk Cell Non Hodgkin Lymphoma C5551485?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Mature T Cell And Nk Cell Non Hodgkin Lymphoma C5551485. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy